LU AA 24493

Drug Profile

LU AA 24493

Alternative Names: Carbamylated EPO; Carbamylated erythropoeitin; Carbamylerythropoietin; CEPO; Lu AA24493

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Warren Pharmaceuticals
  • Developer Lundbeck A/S
  • Class Neuroprotectants; Recombinant erythropoietins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Friedreich's ataxia; Stroke

Most Recent Events

  • 10 Aug 2011 Discontinued - Phase-I for Stroke in European Union (IV)
  • 10 Aug 2011 Discontinued - Phase-I for Stroke in Singapore (IV)
  • 10 Aug 2011 Discontinued - Phase-II for Friedreich's ataxia in Austria (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top